English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
抽象的な
Caffeine in 2019-nCoV: The Co-Evolutionary Protecting Agent
Prakash Krishnan
The current outbreak of COVID‐19 caused by 2019‐nCoV has already taken away plethora of human lives. There is an urgent need for cost effective, available, safe, and effective medicine for fighting this virus. As on date, there is no specific medication available for COVID-19. The bitter taste receptor -TAS2R family (present in human airway smooth muscle) is an important player in host defence mechanisms. Considering the caffeine role as bitter agonists to stimulate the TAS2Rs and to activate host defence mechanisms and to suppress the cytokine storms due to its anti-inflammatory action, caffeine can play as an agent for support therapy in the control of SARS-COV-2. Studies demonstrate that caffeine apart from its role as a central nervous system stimulant has proven the ability as an antiviral agent by its role in inhibiting viral protein synthesis. This article is an approach to attract the attention of caffeine researchers to highlight onto the possibilities and suggest the population with beneficial and accessible remedies.